



# House of Representatives

General Assembly

**File No. 161**

January Session, 2013

House Bill No. 5347

*House of Representatives, March 26, 2013*

The Committee on General Law reported through REP. BARAM of the 15th Dist., Chairperson of the Committee on the part of the House, that the bill ought to pass.

## ***AN ACT CONCERNING PRESCRIPTION DRUG LABELS.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. Section 20-617 of the general statutes is repealed and the  
2 following is substituted in lieu thereof (*Effective January 1, 2014*):

3 (a) Each pharmacist shall include on the label of each prescription  
4 container: (1) The quantity of prescribed drug placed in such container,  
5 in addition to any other information required by law; and (2) a  
6 prominently printed expiration date based on the manufacturer's  
7 recommended conditions of use and storage that can be read and  
8 understood by the ordinary individual. The expiration date required  
9 pursuant to subdivision (2) of this section shall be no later than the  
10 expiration date determined by the manufacturer.

11 (b) If a nonbrand name drug is dispensed, each pharmacist shall  
12 include the name of the brand name and name of the generic drug on  
13 the label of the prescription container. The information required  
14 pursuant to this subsection shall be in the following form, with the

15 generic name and brand name inserted as appropriate: "\_\_\_\_\_ Generic  
16 for\_\_\_\_\_."

This act shall take effect as follows and shall amend the following sections:
---

Section 1	<i>January 1, 2014</i>	20-617
-----------	------------------------	--------

**GL**      *Joint Favorable*

The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

---

**OFA Fiscal Note**

**State Impact:** None

**Municipal Impact:** None

**Explanation**

There is no fiscal impact to the Department of Consumer Protection (DCP) in requiring pharmacists to label generic prescription drugs with both the generic name of the drug and the brand name as the DCP already acts upon related consumer complaints and few additional complaints are anticipated.

**The Out Years**

**State Impact:** None

**Municipal Impact:** None

**OLR Bill Analysis****HB 5347****AN ACT CONCERNING PRESCRIPTION DRUG LABELS.****SUMMARY:**

This bill requires pharmacists to label generic prescription drugs with both the generic name of the drug and the brand name, in the form: “\_\_\_\_\_ Generic for \_\_\_\_\_.” Currently, the brand name is not required on generic drug labels.

EFFECTIVE DATE: January 1, 2014

**BACKGROUND*****Related Law - FDA Regulation of Prescription Drug Labeling***

The U.S. Food and Drug Administration (FDA) regulates prescription drug labeling and preempts state regulation in some areas. The U.S. Supreme Court ruled that the FDA did not have exclusive jurisdiction over prescription drug labeling in a case that allowed a lawsuit for damages to proceed against a brand name drug manufacturer based on a state law claim of inadequate warning labels (*Wyeth v. Levine*, 129 S.Ct. 1187 (2009)). But, the Court found that a similar state law claim against a generic manufacturer conflicted with and was preempted by federal regulations that required generic drug labels to be identical to FDA-approved labels (*Pliva, Inc. v. Mensing*, 131 S.Ct. 2567 (2011)). The preempted suit could have resulted in requiring a generic drug manufacturer to update labeling to reflect newly discovered side effects, something the manufacturer could not legally do alone, without the FDA acting.

**COMMITTEE ACTION**

General Law Committee

Joint Favorable

Yea    15    Nay   3    (03/12/2013)